At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 36 enrolled
Drug / intervention
fluorothymidine F 18drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Improving Pelvic Cancer Patient Chemoradiotherapy Outcomes With FLT PET Imaging
In Brief
A Phase 2 clinical trial evaluating fluorothymidine F 18 for Uterine Cervical Neoplasms and 4 related conditions. Completed, enrolled 36 participants across 1 site.
Detailed Summary
\[F-18\] Fluorothymidine PET imaging will be used to create a radiation therapy treatment plan to avoid active bone marrow in the pelvis. This will be done to evaluate if sparing bone marrow will help maintain blood counts. This would impact chemotherapy administration.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUterine Cervical Neoplasms, Endometrial Neoplasms, Anus Neoplasms, Rectal Neoplasms, Prostatic Neoplasms
CountriesUnited States
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2012
First PostedOct 2012
Primary CompletionFeb 2016
Study CompletionApr 2017
TodayJul 2026
First PostedOct 30, 2012
Enrollment StartOct 1, 2012
Primary CompletionFeb 29, 2016
Study CompletionApr 30, 2017
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 13.7 years ago
Interventions
fluorothymidine F 18drug
A patient-specific bone marrow map will be designed from the pre-therapy FLT PET/CT imaging. A highly conformal radiation plan will be designed to spare active bone marrow.